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A B S T R A C T
In this study we analyzed the effect of polymorphic variation of NAD(P)H: quinone oxidoreductase1 (NQO1) gene that
encode enzyme which detoxifies harmful quinines and protect hematopoietic stem cells against oxidative stress. C609T
polymorphism of NQO1 gene leads to loss of enzyme activity, which may be a risk factor in the etiology of specific types of
hematopoietic malignancies.We analyzed C609T polymorphism in NQO1 gene in the group of 82 patients (56 adult and
26 children) with different type of hematopoietic malignancies and 99 healthy participants (61 adult and 38 children)
using PCR and the RFLP method. We confirmed that the polymorphism C609T in NQO1 gene was more frequent in the
adult patients’ group with myeloid disorders, (p=0.0267) compared with adult controls. We could not confirm the associ-
ation C609T polymorphism with recurrent chromosome translocations (clonal karyotype changes) neither in the adult
nor in pediatric group of patients.
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Introduction
The World Health Organization (WHO) classifies he-
matological malignant diseases according to their lineage
(myeloid, lymphoid, histiocytic/dendritic) and distingui-
shes neoplasm of precursor cells from those comprised of
functionally mature cells. Within each category, distinct
diseases are defined according to a combination of mor-
phology, immunophenotype, genetic futures and clinical
syndromes1. Acute lymphoblastic leukemia (ALL) is the
most common type of leukemia in early childhood while
primary myeloid disorder (acute or chronic) is the most
common type of leukemia in the elderly2.
From a clinical point of view it is very important to
understand myeloid and lymphoid classification of neo-
plasm3. Hematopoietic malignancies are clonal diseases
that arise due to genetic changes in one hematopoietic
stem cell in the bone marrow or lymph tissue4. Such al-
tered cell divides forming abnormal clone of cells, which
can be determined by cytogenetic findings of the same or
similar changes in three metaphases5. Series of low-
-penetrance genes can be involved in the development of
hematological malignant diseases. An individual’s risk of
complex disease development presents a cumulative ef-
fect of genetic and environmental factors. It seams that
polymorphisms of certain genes play a role in leuke-
mogenesis6.
Therefore, in this study we analyzed the polymor-
phism of the NQO1 gene that encode protein responsible
for detoxification of endogenous and exogenous muta-
gens and may influence susceptibility to leukemia deve-
lopment6–11.
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NAD(P)H: quinine oxidoreductase1 (NQO1) is a de-
toxification enzyme that protects cells against oxidative
stress and toxic quinines (11). NQO1 catalyze a 2-elec-
tron reduction of quinines, causing prevention of their
participation in redox cycling and thus in oxidative
stress6.
Individuals with a lack of NQO1 activity are more
susceptible to the toxic and carcinogenic effects of qui-
nines (reactive metabolites of benzene) and have in-
creased risk of hematotoxicity and leukemia6,12. The hu-
man NQO1 gene is located on chromosome 16q22.1 and
has six exons (13). Polymorphism C to T at position –609
causes proline to serine substitution in codone 187 in the
NQO1 protein. Homozygous T/T show the loss of enzyme
activity, and heterozygous C/T show low to intermediate
NQO1 activity. It has been reported that children are
particularly more vulnerable than adults to oxidative
stress and toxic quinines because their metabolism is less
developed/matured, and they have a higher level of cell
division and growth6,12.
In this case-control study, we analysed whether the
NQO1 variation increase risk for an individual’s suscep-
tibility to hematological malignancies. Our study was
conducted in Southern Croatian population, which can
be considered relatively homogenous from both genetic
and socio-cultural points of view.
Material and Methods
In this study we investigated 82 patients (34 females
and 48 males) and 99 healthy participants (45 females
and 54 males). Investigated group of patients was divided
according to the age in two groups. Most of the patients
(56 individuals) were of adult age (median age 58 years;
range 34–82 years) with different types of myeloid neo-
plasms. The rest of them were pediatric patients (26 indi-
viduals) (median age 8.5 years; range 0.3–17 years) with
prevalence of lymphoid neoplasms (20 individuals). The
group of healthy participants (61 adult and 38 pediatric
individuals) has been adjusted in age and sex distribu-
tion with patient group. The cases had been diagnosed in
the Department of Pediatric and Internal Medicine of
Split University Hospital between 2002 and 2007. The
diagnosis was established according to standard rules of
the WHO classification. All patients were karyotyped us-
ing previously described methods of cytogenetic analysis
on pretreatment bone marrow cells14.
In our study we investigated C609T polymorphism of
the NQO1 gene (rs1800566) using previously described
standard methods15. For detection of C609T polymor-
phism, we performed the polymerase chain reaction (PCR)
and restriction fragment length polymorphism (RFLP)
after digestion with restriction enzyme HifnI. The di-
gested fragments were separated and visualized on aga-
rose or polyacrylamide gels. Fragments of 151, 120, and
33 bp on gels confirmed the presence of the polymorphic
HinfI restriction site yields.
NQO1 genotype frequencies in leukemia subgroups
and controls were compared by the c2-test. P-values less
than 0.05 were considered nominally significant. Statis-
tical analysis was performed using statistical package
MedCalc (Mariakerke, Belgium).
Results
The distribution of C609T genotypes of the NQO1
gene, in the adult patient group with myeloid disorder
and adult controls are reported in Table 1. Genotype fre-
quencies showed statistically significant difference be-
tween those two groups (p=0.0267).
A heterozygote (C/T) genotype was most frequent in
the group of unclassifiable myeloproliferative neoplasms
(MPN) (7/15).
Recurrent chromosome abnormalities (clonal abnor-
malities) detected in the leukemia cells of the adult pa-
tient group showed a wide spectrum of clonal karyotype
aberrations, and were found in 25/56 patients (12 of
them were C609T heterozygous). The most frequent
clonal rearrangement was reciprocate translocation
t(9;22) observed in 14 patients exclusively with chronic
myelogenous leukemia BCR-ABL positive (CML), (5 het-
erozygous). Heterozygote genotypes were also found in
patients with other different clonal abnormalities [dele-
tion in chromosome 20q (2/2) and different abnormalities
which include chromosome 17q (3/3). However, no associ-
ation was found between specific chromosomal abnor-
malities and C609T genotypes of the NQO1 gene.
The distribution of genotypes in the NQO1 gene, in
the pediatric leukemia patient group compared with pe-
diatric control group is reported in Table 2 and statistical
significant difference was not found (p=0.1282).
A heterozygote (C/T) genotype was most frequent in
the group of the acute lymphoblastic leukemia (8/20).
The C609T genotypes of NQO1 gene also were not re-
lated to specific clonal abnormalities in pediatric patient
group.
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TABLE 1
NQO1 C609T GENOTYPES AMONG ADULT MYELOID NEOPLASM
SUBTYPES IN THE 56 INVESTIGATED AND 61 CONTROL
SUBJECTS
GROUPS C/C C/T T/T Chi square p value
Control group 48/61 12/61 1/61
Patient group 31/56 23/56 2/56 7.25 0.026
Subtypes of adult myeloid neoplasm No/Total
MPN (unclassifiable) 7/15 7/15 1/15 15/56
CML 9/14 5/14 0/14 14/56
PV 5/9 3/9 1/9 9/56
MDS 5/8 3/8 0/8 8/56
AML 7/10 3/10 0/10 10/56
MPN=Myeloproliferative neoplasm; CML = Chronic myeloge-
nous leukemia; BCR-ABL positive; PV = Polycythemia vera; MDS
=Myelodysplastic syndromes; AML=Acute myeloid leukemia.
Discussion
We confirmed that homozygote T/T and heterozygote
C/T genotypes of NQO1 C609T polymorphism were sig-
nificantly more frequent in the investigated group of
adult patients with different myeloid disorders. These re-
sults suggest that presence of a polymorphic T allele rep-
resent a risk factor for the development of primary
myeloid disorder in adults, which is associated with a re-
duced amount or lack of enzyme involved in the detoxifi-
cation of quinone carcinogens.
NQO1 C609T allele frequency varies between differ-
ent ethnic groups. The frequency of allele T of the NQO1
C609T polymorphism in white populations of Europe
and America is lower (17% in the United Kingdom, 19%
in Germany and 16% USA) compared with Asia and Mex-
ican Hispanic populations where it is significantly higher
(42% in Korea, 47% in China, 38% in Japan, and 43% in
Mexico)12,16. The allele T frequency among healthy indi-
viduals (adults and children), in our Southern Croatian
population was 11% what is the expected frequency for
the Caucasian population.
Larson et al as well as Yamaguti et al in their studies
of different ethnic groups, mostly Caucasians, showed a
significant difference in frequency of heterozygous (C/T)
and homozygous (T/T) between patients with myeloid
disorders and controls what is in concordance with our
results15,17.
Study performed in a Japanese population, showed a
similar frequency of C/T and T/T genotypes in patient
group but they could not reach statistical significance be-
cause of a higher frequency of the T allele in the healthy
Japanese population18. An Israel study, conducted by
Malik et al, showed that the frequency of C/T allele did
not differ between AML patients and control subjects be-
cause of more frequent T allele in healthy population19.
The study conducted in the Franch-Canadian prov-
ince of Québec, Canada showed a significantly more fre-
quent polymorphic T allele in the group of pediatric pa-
tients with acute lymphoblastic leukemia (ALL)6. In con-
trast to those, our results did not show association of
NQO1 C609T polymorphism with pediatric leukemia.
Sirma et al in Turkish population also found that NQO1
C609T polymorphism is not associated with de novo pe-
diatric acute leukemia in their study group12. Recently a
meta-analysis of seven studies that analyzed the risk of
de novo pediatric leukemia was conducted. Pooling data
from seven studies, authors provided no evidence of a re-
lationship between NQO1 C609T genotype and risk for
pediatric leukemia20. Yeoh AE et al in Asians population
as well as Silveira Vda S et al in Brazilian population
showed that carriers of NQO1 CT genotype have a lower
risk of developing ALL compared to those carrying wild-
-type21,22. This finding was in contrast to nearly all previ-
ous reports in the Caucasians. Probably racial and socio-
-cultural heterogeneity of populations can cause such
divergent results.
We could not confirm association of C609T polymor-
phism with specific cytogenetic abnormalities in a kar-
yotype. Karyotype was not found to be associated with a
heterozygote (C/T) genotype in Israeli group of patients
what is in concordance with our results19. However,
Larson et al found that the T allele frequency was a 1.6
fold higher in the patients with chromosomal aberrations
(chromosome 5 and 7), while Smith et al showed the
same in patients with inversion of chromosome 1615,10.
In summary, the frequency of an inactivating poly-
morphism of NQO1 gene appears to be increased among
primary myeloid disorders in adults, while we did not
provide evidence for the statistically significant effect of
this polymorphism in pediatric leukemia. No evidence
was found in association of cytogenetic findings and inac-
tivating polymorphism of NQO1 gene in both groups of
patients. These results suggests that inactivating poly-
morphism of functional genetic marker involved in the
metabolic pathway of carcinogens may be a risk factor in
leukemogenesis of specific types of hematopoietic malig-
nancies in a certain age. Further research should include
a larger number of genetically homogenous subjects.
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ANALIZA POLIMORFIZMA C609T GENA ZA NQO1 U BOLESNIKA S HEMATOLO[KIM MALIGNIM
BOLESTIMA U JU@NOJ HRVATSKOJ
S A @ E T A K
U ovoj studiji analizirali smo utjecaj polimorfnih varijanti gena za NAD(P)H: kvinon oksidoreduktaza1 (NQO1) koji
kodira enzim za detoksikaciju {tetnih kvinona i {titi hematopoetske mati~ne stanice od oksidativnog stresa. Polimor-
fizam C609T gena za NQO1dovodi do gubitka enzimske aktivnosti {to mo`e biti rizi~ni ~imbenik u etiologiji specifi~nih
tipova hematopoetskih malignih bolesti. Analizirali smo polimorfizam C609T gena za NQO1 u grupi od 82 bolesnika
(56 odraslih i 26 djece) s razli~itim tipovima hematopoetskih malignih bolesti te u 99 zdravih ispitanika (61 odrasli i 38
djece) koriste}i metode PCR i RFLP. Potvrdili smo da je polimorfizam C609T gena za NQO1 u~estaliji u skupini odraslih
s mijeloidnim poreme}ajima, (p=0,0267) u usporedbi s kontrolnom skupinom odraslih ispitanika. Nismo mogli potvr-
diti povezanost polimorfizma C609T s odre|enim kromosomskim translokacijama (promjene klonalnog kariotipa) ni u
odrsloj kao ni u pedijatrijskoj skupini oboljelih.
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